497 Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam

2016 ◽  
Vol 15 (3) ◽  
pp. e497-e497a
Author(s):  
A. Alberts ◽  
M. Roobol ◽  
L. Bokhorst ◽  
F-J. Drost ◽  
G. Van Leenders ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Guided Biopsy

scholarly journals The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication

2019 ◽  
Vol 120 (05) ◽  
pp. 331-335
Author(s):  
J. Breza ◽  
F. Subin ◽  
M. Bernadic ◽  
M. Tomas ◽  
D. Pindak
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Diagnostic Tool ◽  
Randomized Study

The Incidence of Prostate Cancer in Men With Prostate Specific Antigen Greater Than 4.0 Ng/Ml:: A Randomized Study Of 6 Versus 12 Core Transperineal Prostate Biopsy

2004 ◽  
Vol 171 (1) ◽  
pp. 197-199 ◽  
Author(s):  
PAOLO EMILIOZZI ◽  
PAOLO SCARPONE ◽  
FRANCESCO DePAULA ◽  
MAURIZIO PIZZO ◽  
GIORGIO FEDERICO ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Specific Antigen ◽  
Transperineal Prostate Biopsy

scholarly journals MRI-TRUS fusion guided prostate biopsy – initial experience and assessment of the role of contralateral lobe systematic biopsy

2019 ◽  
Vol 21 (1) ◽  
pp. 37
Author(s):  
Iulia Andras ◽  
Dana Crisan ◽  
Emanuel Cata ◽  
Attila Tamas-Szora ◽  
Cosmin Caraiani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Initial Experience ◽  
Positive Biopsy ◽  
Guided Biopsy ◽  
Diagnosis Rate ◽  
The Mean ◽  
Clinically Significant ◽  
Systematic Biopsy

Aims: To present our initial experience and results of MRI-TRUS fusion guided prostate biopsy and assess the role of contralateral lobe systematic biopsy.Material and method: A number of 119 patients with clinical or biochemical suspicion for prostate cancer (PCa) were included. All patients harbored at least one PIRADS score ≥ 3 lesion and underwent MRI-TRUS fusion guided biopsy, as well as a concurrent systematic biopsy. The biopsy was performed by the same operator, using a rigidregistration software system.Results: The mean age of the patients was 62.2 years. The mean pre-biopsy PSA was 9.15 ng/dl. The diagnosis rate of MRI-TRUS fusion guided biopsy was 47% for overall PCa and 29.4% for clinically significant (cs) PCa. A higher PIRADS score was significantly associated with the presence of overall and csPCa. MRI-TRUS fusion guided biopsy had a higher percentage of positive biopsy cores (51% vs 29%), higher likelihood of csPCa (OR 5.36, p=0.008) and upgrading (14.8%) in comparison with systematic biopsy but missed 6.7% csPCa. The contralateral lobe systematic biopsy could have been avoided without losing the PCa diagnosis all patients with PIRADS score 5, both in initial and repeat biopsy setting. Anterior and transitional lesions were more likely to be diagnosed only by targeted cores.Conclusion: MRI-TRUS guided prostate biopsy improves the detection of PCa, but systematic biopsy is still essential. In selected cases (PIRADS 5), contralateral lobe systematic biopsy can safely be avoided. Pre-biopsy mpMRI might reduce the number of biopsy sessions in patients with anterior and transitional lesions.

Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

2017 ◽  
Vol 120 (3) ◽  
pp. 394-400 ◽  
Author(s):  
Peter K. Chiu ◽  
Arnout R. Alberts ◽  
Lionne D. F. Venderbos ◽  
Chris H. Bangma ◽  
Monique J. Roobol
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Additional Benefit ◽  
Selection For ◽  
Biopsy Complications

The validity of repeat prostate biopsy in prior biopsy negative patients: MRI-TRUS fusion guided biopsy.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 95-95
Author(s):  
Jinho Hwang ◽  
Jung Jun Kim ◽  
Jong Jin Oh ◽  
Chang Wook Jeong ◽  
Sangchul Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Statistical Significance ◽  
Transrectal Ultrasound ◽  
Negative Results ◽  
Guided Biopsy ◽  
Clinically Significant ◽  
Magnetic Resonance Imaging Mri ◽  
Target Biopsy

95 Background: To investigate validity of magnetic resonance imaging (MRI)-transrectal ultrasound fusion target biopsy (Fusion-Bx) compared with transrectal ultrasound-guided biopsy (TRUS-Bx) by evaluating detection rate of prostate cancer (PCa). Methods: Medical records of 376 patients with prior negative TRUS-Bx who underwent repeat prostate biopsy between Aug. 2015 and Apr. 2017 were retrospectively reviewed. The cohort was stratified into two groups (TRUS-Bx and Fusion-Bx) and clinical and biopsy characteristics patterns were analyzed. Conventional systemic randomized 12-core biopsy was performed in TRUS-Bx group whereas Fusion-Bx group applied additional 2-croes of target biopsy against suspicious lesions in MRI. Results: There were total 195 and 181 patients in TRUS-Bx and Fusion-Bx group, respectively. The overall cancer detection rate was slightly higher in Fusion-Bx group, but no statistical significance was observed (24.6% vs 28.7%, p = 0.367). Fusion-Bx group showed a significantly greater detection rate in target core analysis (5.0% vs 17.7%, p = 0.044). In confirmed positive biopsy patients, Fusion-Bx group had a higher rate of clinically significant prostate cancer (CsPCa) cases, but failed to achieve statistical significance (85.4% vs 92.3%, p = 0.271). When the patients with highly or very highly suspicious MRI (maximum image grade 4-5) findings in Fusion-Bx group was compared to the whole cohort of TRUS-Bx group, Fusion-Bx group was significantly greater in terms of overall detection rate (24.6% vs 38.0%, p = 0.017) and CsPCa detection rate (85.4% vs 97.0%, p = 0.009). Higher the target image grade, greater biopsy yield was achieved. Conclusions: For the patients who underwent repeat biopsy due to prior negative results, fusion-Bx showed better clinical significance including detection rate. A further study with a larger cohort size and prospective design is still needed to confirm the validity of Fusion-Bx.

Multi-parametric MRI prostate PIRAD scoring in a district general hospital: Correlating PIRADS 3 results with histological findings

2021 ◽  
Author(s):  
Sarmad Aslam ◽  
Jeffrey Tsang ◽  
Ian Bickle ◽  
Ali Saiepour
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Perineal Ultrasound ◽  
Ultrasound Guided ◽  
Mri Findings ◽  
Mri Scan ◽  
Prostatic Volume ◽  
Guided Biopsy ◽  
Malignant Lesions ◽  
Ultrasound Guided Biopsy

Objective: Prostate cancer is the most common male cancer in the UK. In many hospitals, patients are now being referred for a multi parametric (mp) MRI scan of their prostate as part of an evaluation for the presence of prostate cancer, prior to an ultrasound guided biopsy. PI-RADS score of 3 are defined as “equivocal” for the presence of prostate cancer. Thus, a PIRADS three lesion does not confidently determine whether there is significant prostate disease or not. Our aim is to determine the correlation of PIRADS three prostatic lesions with histology proven, clinically significant cancer. Methods: We performed a retrospective review on a cohort of 143 consecutive patients. Each patient underwent a mp-MRI scan of their prostate given a PIRADS score. PIRADS three lesions were analysed further based on histology and categorised into malignant and non-malignant lesions. PSA results and prostatic volume of PIRADS three lesions were also analysed. Results: We identified forty five patients with PIRADS 3 lesions out of 143 patients. Thirty-two patients subsequently underwent trans-rectal/trans-perineal ultrasound guided biopsy. 43% of patients were found to have had a malignant prostatic adenocarcinoma on histology. The remaining 56% had non-malignant findings. Of those with malignant disease, there was a higher median PSA and lower mean prostatic volume. Conclusions: The study confirms that a score of PIRADS three does not accurately differentiate between malignant and non-malignant lesions. Further investigations such as ultrasound-guided prostate biopsy and PSA parameters are required to accurately ascertain the nature of a prostate lesion with PIRADS score 3. Advances in knowledge: An ultrasound-guided prostate biopsy in patients with PIRADS 3 remains of paramount importance when distinguishing malignant versus non-malignant lesions. Multicentre data of MRI findings with PIRADS three scores is required to yield a sample size large enough to carry out statistical analysis.

scholarly journals Redefining Serum PSA Cut-off in Indian Population to Avoid Unnecessary Biopsies - A Descriptive Study

2021 ◽  
Author(s):  
Javangula Venkata Surya Prakash ◽  
Thiruvarul PV ◽  
Vetrichandar Sattanathan ◽  
Krishnan Vembu Arasi ◽  
ArunKumar Paranjothi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Indian Population ◽  
Specific Antigen ◽  
Cancer Detection Rate ◽  
Asian Countries ◽  
Western Countries ◽  
Guided Biopsy

Abstract INTRODUCTION: Prostate cancer is the second most common cancer diagnosed in men with an estimated 1.2 million diagnoses worldwide. The incidence of Prostate cancer is higher in western countries and low in Asian countries. The need for prostate biopsy is based on PSA levels. The general cut off PSA value for the Indian population is 4.0 ng/mL. The reported cancer detection rate of TRUS-guided biopsies is around 30 percent in western countries and lesser in Asian countries, including India, particularly for serum PSA values less than 20 ng/mL indicating that many of the Indian patients are subjected to unnecessary biopsy which adds up to distress to these patients.PURPOSE: To determine the cancer detection rate of TRUS-guided prostate biopsy in the Indian population at different serum Prostate-Specific Antigen levels and determine a PSA cut-off level to avoid unnecessary biopsies.MATERIALS AND METHODS:All symptomatic patients who underwent TRUS guided biopsy for raised serum PSA levels between 4 - 20 ng/mL were included. The patients were categorized into four groups corresponding to the PSA levels ranging between 4-6 ng/mL, 6- 8 ng/mL, 8-10 ng/mL, and 10-20 ng/mL respectively, and cancer detection rate in each group were statistically analyzed.RESULTS:The sensitivity, specificity, and positive predictive value of TRUS guided biopsy are 75%, 95%, and 98% respectively in our study. The overall cancer detection rate of TRUS biopsy in our series was 18.4%. The PSA cut-off to do biopsy was derived by ROC curve as 8.9 ng/ml for all the men. CONCLUSION: The PSA cut-off of 4.0 ng/mL is currently used as an indication for biopsy among men of all ages in the Indian population. We recommend a raise in cut-off to 8.9 ng/mL to avoid unnecessary TRUS-guided biopsies in the Indian population.

Sign in / Sign up

Export Citation Format

Share Document